Surgeons’ at the NYU Langone Medical Center have been successfully using MarginProbe in patients with early stage breast cancer.
The presence of tumor cells at the margins of breast lumpectomy specimens is associated with an increased risk of tumor recurrence. Evidence has shown that 20-30 % of patients undergoing breast-conserving surgery require second procedures to achieve negative margins.
The Division of Breast Surgery at the NYU Langone was the pioneer institution in New York City to use this novel technology, called MarginProbe device (Dune Medical Devices Ltd, Caesarea, Israel), which provides real-time intraoperative assessment of lumpectomy margins.
This technique was found to improve surgeon’s ability to identify and resect cancer with margins, thus reducing the number of patients requiring re-excision.